Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 09/28 10:00:21 pm
63.3 USD   +1.17%
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Dire..
09/28 MSD ANIMAL HEAL : Demonstrates Commitment to Eliminate Rabies Worldw..
09/28 MERCK : Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : FDA Denies Merck Request to Block Generic Form of Nasonex

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/19/2012 | 08:47pm CEST
   By Peter Loftus 
 

Merck & Co. (MRK) lost another round in its effort to block a competing generic copy of its Nasonex allergy nasal spray from entering the U.S. market.

The U.S. Food and Drug Administration this month denied Merck's petition asking the agency not to approve applications by generic drug makers to sell certain proposed generic forms of Nasonex. Merck, of Whitehouse Station, N.J., had argued the FDA shouldn't approve any proposed generic copy that has a different formulation than Nasonex.

The FDA denial of Merck's petition follows a federal court ruling earlier this year finding that Apotex Corp.'s proposed generic version of Nasonex doesn't violate a Merck patent for the drug. Merck has appealed that patent ruling.

Both developments remove some obstacles to the market entry of competing generic versions of Nasonex before patent protection expires in 2018, which would hurt sales of the branded drug. The drug, which Merck obtained in its 2009 purchase of Schering-Plough, generated $960 million in sales for the first nine months of 2012.

Canada's Apotex wants to sell a generic version of Nasonex that is slightly different from the original. The proposed Apotex product would have the same active ingredient, mometasone furoate, but in a non-water formulation, whereas Merck's product has a water component.

In 2009, Merck filed a patent-infringement lawsuit against Apotex in response to Apotex's application to market the generic product. Apotex argued that its proposed product wouldn't infringe upon Merck's patent because it would be a non-water formulation of mometasone furoate.

Following an April trial in federal court in Trenton, N.J., U.S. District Judge Peter G. Sheridan in June ruled that Apotex's proposed product wouldn't infringe upon the Merck patent, though the judge upheld the patent's validity. Merck has appealed the ruling.

In July, Merck filed a so-called citizen petition asking the FDA to refrain from approving any application for a non-water version of Nasonex that relies upon clinical data for the original drug. Merck argued that the non-water version couldn't be considered as the pharmaceutical equivalent to Nasonex because there would likely be differences in how they are absorbed in the body.

Lawyers for Apotex objected to Merck's request in a November comment letter to FDA, saying there was established precedent for the agency to approve generic versions of branded drugs that contain slightly different forms of the same active ingredient.

In a Dec. 7 letter, the FDA denied Merck's petition, saying that a non-water form of mometasone could potentially be considered pharmaceutically and therapeutically equivalent to the water-based Nasonex, assuming other requirements are met.

"We were disappointed with the decision on the citizen petition," said Merck spokesman Ronald Rogers.

The FDA denial of Merck's petition doesn't amount to approval of Apotex's generic product; that review is pending.

Apotex spokesman Steve Giuli declined to comment.

Merck shares declined 38 cents to $43.85 Wednesday.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
09/28 MSD ANIMAL HEALTH : Demonstrates Commitment to Eliminate Rabies Worldwide with D..
09/28 MERCK : Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy..
09/23DJMERCK : Keytruda Finds Fast Entry Into China Via Medical-Tourism Push
09/23 MERCK : to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October..
09/21 MERCK : Geneva Advisors Lowers stake in Merck & Co. (MRK)
09/20 MERCK : to Host Investor Teleconference to Discuss ESMO 2016 Highlights
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/20DJBusiness Watch -- WSJ
09/20DJBullish Bayer Boss Defends Monsanto Deal
More news
Sector news : Pharmaceuticals - NEC
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:13a Yellen And Clinton Combo To Take Market Higher
09/28 Enrollment underway in Bayer and Merck's large-scale study of vericiguat in h..
09/27 Real Estate Leader CXW Gains Upside As Price Sags
09/26 Enrollment underway in Gemphire's mid-stage study of gemcabene in patients wi..
09/23 Industrial Sector Capped By Ships & Ports In September
Advertisement
Financials ($)
Sales 2016 39 719 M
EBIT 2016 13 608 M
Net income 2016 5 662 M
Debt 2016 5 481 M
Yield 2016 2,87%
P/E ratio 2016 30,73
P/E ratio 2017 20,81
EV / Sales 2016 4,54x
EV / Sales 2017 4,48x
Capitalization 175 038 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,1 $
Spread / Average Target 4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.19.84%175 038
JOHNSON & JOHNSON16.23%326 636
ROCHE HOLDING LTD.-12.41%217 190
NOVARTIS AG-10.14%212 589
PFIZER INC.5.30%206 172
GLAXOSMITHKLINE PLC20.54%105 036
More Results